{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(5)"],"submitter":["Bailey TS"],"funding":["Eli Lilly and Company"],"pubmed_abstract":["<h4>Introduction</h4>To evaluate time in range metrics and HbA1c in people with type 2 diabetes (T2D) treated with ultra rapid lispro (URLi) using continuous glucose monitoring (CGM) for the first time in this population.<h4>Methods</h4>This was a Phase 3b, 12-week, single-treatment study in adults with T2D on basal-bolus multiple daily injection (MDI) therapy using basal insulin glargine U-100 along with a rapid-acting insulin analog. Following a 4-week baseline period, 176 participants were newly treated with prandial URLi. Participants used unblinded CGM (Freestyle Libre). Primary endpoint was time in range (TIR) (70-180 mg/dl) during the daytime period at Week 12 compared to baseline with gated secondary endpoints of HbA1c change from baseline and 24-h TIR (70-180 mg/dl).<h4>Results</h"],"journal":["Diabetes therapy : research, treatment and education of diabetes and related disorders"],"pagination":["883-897"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10081815"],"repository":["biostudies-literature"],"pubmed_title":["Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range."],"pmcid":["PMC10081815"],"pubmed_authors":["Bode BW","Wang Q","Knights AW","Chang AM","Bailey TS"],"additional_accession":[]},"is_claimable":false,"name":"Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range.","description":"<h4>Introduction</h4>To evaluate time in range metrics and HbA1c in people with type 2 diabetes (T2D) treated with ultra rapid lispro (URLi) using continuous glucose monitoring (CGM) for the first time in this population.<h4>Methods</h4>This was a Phase 3b, 12-week, single-treatment study in adults with T2D on basal-bolus multiple daily injection (MDI) therapy using basal insulin glargine U-100 along with a rapid-acting insulin analog. Following a 4-week baseline period, 176 participants were newly treated with prandial URLi. Participants used unblinded CGM (Freestyle Libre). Primary endpoint was time in range (TIR) (70-180 mg/dl) during the daytime period at Week 12 compared to baseline with gated secondary endpoints of HbA1c change from baseline and 24-h TIR (70-180 mg/dl).<h4>Results</h","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-07-14T19:13:02.317Z","creation":"2025-04-04T14:29:54.34Z"},"accession":"S-EPMC10081815","cross_references":{"pubmed":["37029268"],"doi":["10.1007/s13300-023-01400-w"]}}